Debu tripathy biography of christopher

He serves on several editorial boards, study sections, and societies, and he is the editor-in-chief of CURE Magazine. Many different tests can be involved in a metastatic breast cancer diagnosis. These tests can confirm the extent of the cancer and determine the most effective treatments. Trastuzumab Herceptin is the most common medicine used to treat HER2-positive breast cancer.

Tripathy D. March; Miami, Florida. Conferences Conference Coverage Conference Listing. Resources Interactive Tools Sponsored. Choose Specialty Biosimilars. Brain Cancer. Breast Cancer Breast Cancer. CAR T-cell Therapy. Disparities in Cancer Care. Global Oncology. Gynecologic Oncology Gynecologic Oncology. Lung Cancer. Oncology Business Management.

Pediatric Oncology. Supportive Care. Author s : Kyle Doherty. In Partnership With:. Debu Tripathy, MD. Related Videos. Related Content. Latest Conference Coverage. He has developed an antibody now that can cause stem cells to mature or to die, so if combined with chemotherapy, one may be able to eradicate the whole tumor leaving no residual cells.

We want to understand what drug we should combine with stem cell inhibitors, and how to use that information and move it into the clinic, which we hope to do in a year and a half. Q: Please discuss your recent efforts to understand more about resistance to Herceptin. We found it by looking at a gene array profile in a cell we made resistant to Herceptin in the lab.

We looked at multiple genes in the cancer cell to see which seemed to be upregulated. We showed that knocking down certain genes recaptured sensitivity to Herceptin, and CXCR4 had the biggest effect. That was an exciting finding, because one of the hardest things in cancer is knowing what the best targets are. A next step will be to take tissue from cancer patients and find out if CXCR4 is expressed more often than in Herceptin-resistant tumors.

At Duke, he worked with Richard S. Metzgar, PhD, an immunologist whose lab was among the first to develop monoclonal antibodies, some of which could inhibit the growth of tumors in animals. We showed that you can actually slow down the growth of breast cells. Tripathy and his fellow researchers also discovered that several antibodies could shut down the growth of breast cancer cells.

After finishing his fellowship, Tripathy stayed with UCSF for 11 years, ending his time there as an associate clinical professor of Medicine. In my lab, we discovered several genes involved in Herceptin resistance. Between those efforts and the start of his work at USC, Tripathy took 2 years away from his research to turn his attention, once again, to the human side of cancer - in this case, communicating with physicians and patients.

He also serves as editor-in-chief of CURE magazine, whose audience includes cancer patients, survivors, and caregivers. Such activities mark a return to the values that helped spark his interest in medicine during his teenage years, Tripathy said. In high school, Tripathy spent his summers working as a hospital orderly, and enjoyed speaking with patients about their experiences and trying to answer their questions.

Conferences Conference Coverage Conference Listing. Resources Interactive Tools Sponsored. Choose Specialty Biosimilars. Brain Cancer.

Debu tripathy biography of christopher

Breast Cancer Breast Cancer. CAR T-cell Therapy. Disparities in Cancer Care. Global Oncology. Gynecologic Oncology Gynecologic Oncology. Lung Cancer.